RU2723091C2 - Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину - Google Patents

Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину Download PDF

Info

Publication number
RU2723091C2
RU2723091C2 RU2017131900A RU2017131900A RU2723091C2 RU 2723091 C2 RU2723091 C2 RU 2723091C2 RU 2017131900 A RU2017131900 A RU 2017131900A RU 2017131900 A RU2017131900 A RU 2017131900A RU 2723091 C2 RU2723091 C2 RU 2723091C2
Authority
RU
Russia
Prior art keywords
tsc22d4
insulin resistance
inhibitor
recombinant
insulin
Prior art date
Application number
RU2017131900A
Other languages
English (en)
Russian (ru)
Other versions
RU2017131900A3 (enExample
RU2017131900A (ru
Inventor
Штефан ГЕРЦИГ
Маурицио БЕРРИЛЬ ДИАЗ
Тобиас ШАФМАЙЕР
Original Assignee
Дойчес Кребсфоршунгсцентрум Штифтунг Дес Эффентлихен Рехтс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дойчес Кребсфоршунгсцентрум Штифтунг Дес Эффентлихен Рехтс filed Critical Дойчес Кребсфоршунгсцентрум Штифтунг Дес Эффентлихен Рехтс
Publication of RU2017131900A publication Critical patent/RU2017131900A/ru
Publication of RU2017131900A3 publication Critical patent/RU2017131900A3/ru
Application granted granted Critical
Publication of RU2723091C2 publication Critical patent/RU2723091C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017131900A 2015-03-23 2016-02-12 Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину RU2723091C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160259.6A EP3072969A1 (en) 2015-03-23 2015-03-23 Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
EP15160259.6 2015-03-23
PCT/EP2016/053050 WO2016150618A1 (en) 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance

Publications (3)

Publication Number Publication Date
RU2017131900A RU2017131900A (ru) 2019-04-23
RU2017131900A3 RU2017131900A3 (enExample) 2019-06-10
RU2723091C2 true RU2723091C2 (ru) 2020-06-08

Family

ID=52784935

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017131900A RU2723091C2 (ru) 2015-03-23 2016-02-12 Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину

Country Status (11)

Country Link
US (2) US10676739B2 (enExample)
EP (2) EP3072969A1 (enExample)
JP (1) JP2018513841A (enExample)
KR (1) KR20170128348A (enExample)
CN (1) CN107278229A (enExample)
BR (1) BR112017016021A2 (enExample)
DK (1) DK3274455T3 (enExample)
ES (1) ES2837085T3 (enExample)
MX (1) MX384193B (enExample)
RU (1) RU2723091C2 (enExample)
WO (1) WO2016150618A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7289510B2 (ja) * 2019-05-08 2023-06-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
WO2014202602A1 (en) * 2013-06-17 2014-12-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of insulin resistance through inhibitors of transcription factor tsc22d4
RU2573450C1 (ru) * 2014-08-11 2016-01-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ выявления генов-мишеней для диагностики и терапии лейкозов человека

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1692521A1 (en) 2003-12-11 2006-08-23 Beth Israel Deaconess Medical Center, Inc. Rbp4 in insulin sensitivity/resistance, diabetes, and obesity
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US20140227289A1 (en) 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
WO2014202602A1 (en) * 2013-06-17 2014-12-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of insulin resistance through inhibitors of transcription factor tsc22d4
RU2573450C1 (ru) * 2014-08-11 2016-01-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ выявления генов-мишеней для диагностики и терапии лейкозов человека

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
/emmm.201201869. *
Allan Jones et al. "TSC22D4 is a molecular output of hepatic wasting metabolism" EMBO Mol Med (2013) 5, 294-308 *
Allan Jones et al. "TSC22D4 is a molecular output of hepatic wasting metabolism" EMBO Mol Med (2013) 5, 294-308 DOI 10.1002/emmm.201201869. *

Also Published As

Publication number Publication date
MX384193B (es) 2025-03-12
EP3274455A1 (en) 2018-01-31
US20180023078A1 (en) 2018-01-25
US20200255834A1 (en) 2020-08-13
RU2017131900A3 (enExample) 2019-06-10
EP3072969A1 (en) 2016-09-28
BR112017016021A2 (pt) 2018-03-20
RU2017131900A (ru) 2019-04-23
DK3274455T3 (da) 2020-12-14
EP3274455B1 (en) 2020-10-14
JP2018513841A (ja) 2018-05-31
US10676739B2 (en) 2020-06-09
WO2016150618A1 (en) 2016-09-29
CA2979115A1 (en) 2016-09-29
US11053499B2 (en) 2021-07-06
MX2017012231A (es) 2018-01-30
KR20170128348A (ko) 2017-11-22
ES2837085T3 (es) 2021-06-29
CN107278229A (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
DK2217704T3 (en) Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
KR102321426B1 (ko) 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA
EP2283846A1 (en) miRNA compounds for treatment of prostate carcinoma
JP5887413B2 (ja) 非小細胞肺癌におけるｔｍ４ｓｆ４の発現または活性を調節することによって癌細胞の放射線耐性ならびに増殖、転移および浸潤を低減させる方法
US20050153918A1 (en) Methods and compositions relating to hnRNP A1, A1B, A2, and B1 nucleic acid molecules
JP2006519009A (ja) 細胞増殖を阻害する組成物および方法
US11053499B2 (en) Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
JP6479780B2 (ja) 転写因子ｔｓｃ２２ｄ４の阻害剤によるインスリン耐性の治療
KR20230127007A (ko) Ednra 억제제를 유효성분으로 포함하는 대장암의 예방 또는 치료용 약학적 조성물
WO2011054939A2 (en) Compositions and methods for inhibiting expression of kif10 genes
EP1652917A1 (en) Rna capable of inhibiting expression of klf5 gene
CA2979115C (en) Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance
KR100930282B1 (ko) ＮＩＫ 유전자에 대한 ｓｉＲＮＡ 및 이를 포함하는 간질환치료제
KR102707587B1 (ko) miR-4487를 유효성분으로 함유하는 항암제 민감성 증진용 조성물